Merck beats 2Q profit forecasts, lowers guidance

Merck beats 2Q profit forecasts, lowers guidance


1 photo
Save Story
Leer en español

Estimated read time: 2-3 minutes

This archived news story is available only for your personal, non-commercial use. Information in the story may be outdated or superseded by additional information. Reading or replaying the story in its archived form does not constitute a republication of the story.

KENILWORTH, N.J. (AP) — Slightly higher sales and substantial cost-cutting by Merck & Co. boosted second-quarter profit 75 percent, but the drugmaker lowered its financial forecast for the year, citing higher restructuring costs in the quarter.

Meanwhile, increased competition is reducing sales or slowing growth for several of its big sellers, and new drugs in the hot categories of hepatitis C and immune system-boosting cancer drugs are trailing those of rivals dominating those markets.

The Kenilworth, New Jersey, company still edged past Wall Street expectations for profit and it matched sales forecasts.

Shares rose $1, or 1.7 percent, to $59.43 in premarket trading

Merck posted net income of $1.21 billion, or 43 cents per share, up from $687 million, or 24 cents per share, a year earlier. Earnings, adjusted for one-time costs related to mergers and acquisitions and restructuring costs, came to 93 cents per share.

The average estimate of nine analysts surveyed by Zacks Investment Research was for earnings of 92 cents per share.

The second-biggest U.S. drugmaker reported revenue of $9.84 billion in the period, up 1 percent.

Merck said it now expects full-year earnings in the range of $1.98 to $2.08 per share, excluding one-time items. That's down from its May forecast of $1.96 to $2.23.

It expects adjusted 2016 earnings of $3.67 to $3.77 per share, a tighter range than the $3.65 to $3.77 per share it forecast in the spring, and revenue of $39.1 billion to $40.1 billion.

"We remain committed to advancing our pipeline, delivering a balanced and differentiated portfolio, and achieving long-term sustainable growth," CEO Kenneth Frazier said in a statement.

Merck shares have risen 11 percent since the beginning of the year, while the Standard & Poor's 500 index has risen 6 percent. The stock has risen nearly 2 percent in the last 12 months.

_____

Elements of this story were generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on MRK at http://www.zacks.com/ap/MRK

Copyright © The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Photos

Most recent Business stories

Related topics

Business
The Associated Press

    STAY IN THE KNOW

    Get informative articles and interesting stories delivered to your inbox weekly. Subscribe to the KSL.com Trending 5.
    By subscribing, you acknowledge and agree to KSL.com's Terms of Use and Privacy Policy.

    KSL Weather Forecast